Rocakinogene sifuplasmid

司洛吉基

Report date: 2026/05/17 20:00:15

Base Information

Drug NameRocakinogene sifuplasmid
Drug Alias NameDNA Plasmid Encoding Interleukin-12 INO-9012INO-9012
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsVulvar DiseasesUrogenital AbnormalitiesHepatitis, Chronic +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoNew Zealand
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInovio Pharmaceuticals IncGeneos Therapeutics Inc
Inactive CompaniesMedimmune Llc
Active IndicationsHepatitis, ChronicCarcinoma, Transitional CellCarcinoma, Hepatocellular +[5] 
Inactive IndicationsVulvar DiseasesUrogenital AbnormalitiesSquamous Intraepithelial Lesions of the Cervix +[18] 

Other Information

ATC CodeN/A
Related LinksN/A